Status:
COMPLETED
Antiplatelet Strategy for CCS Patients Undergoing CABG
Lead Sponsor:
Samsung Medical Center
Conditions:
Chronic Coronary Syndrome
Coronary Artery Bypass Graft CABG
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the long-term outcomes of different antiplatelet strategies, including DAPT, aspirin monotherapy, and clopidogrel monotherapy, in CCS patients undergoing CABG. A retrospective, population-...
Detailed Description
The use of antiplatelet agents is crucial in preventing atherothrombotic complications and maintaining graft patency after coronary artery bypass grafting (CABG). While dual antiplatelet therapy (DAPT...
Eligibility Criteria
Inclusion
- Patients with underwent Coronary artery bypass surgery (CABG) between January 2010 and December 2020
Exclusion
- In-hospital death
- Not prescribed SAPT or DAPT
- Received CABG due to myocardial infarction or had myocardial infarction
- Received CABG due to unstable angina or had unstable angina
- History of PCI
- Pre-existing Intracranial hemorrhage or gastrointestinal bleeding
- Oral anticoagulant prescription at discharge
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
29898 Patients enrolled
Trial Details
Trial ID
NCT06881901
Start Date
January 1 2010
End Date
December 31 2022
Last Update
March 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.